Superworth

Kiniksa Pharmaceuticals International EV/EBIT KNSA

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2023.

Today, Nov 2, 2026
65.5×
4-year median
50.3×
Against its 4-year history
73rd
percentile: 0 is its lowest day, 100 its highest
4-year range
23.6× to 492×
Peer median
58.4×

Kiniksa Pharmaceuticals International's EV/EBIT is 65.5× as of Nov 2, 2026.

That is above its 4-year median of 50.3×, higher than on 73% of days in the last 4 years.

Over that time it ranged from 23.6× in Oct 2023 to 492× in Aug 2025.

The median for 10 large drugmakers of a similar size is 58.4×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far65.5×35.0×85.9×
202574.5×64.5×492×
2024n/m a value too high to mean anything
202323.6×23.6×68.7×

Against its peers

Companies in Drug Manufacturers - General nearest Kiniksa Pharmaceuticals International's size, closest first, today.

Where Kiniksa Pharmaceuticals International ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Kiniksa Pharmaceuticals International

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.